SCHEMBL19950475

SCHEMBL19950475

Cn1cc(-c2nn(C(=O)OC(C)(C)C)c3ccc(-c4c(F)cc(NC(=O)CCl)cc4F)cc23)cn1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAP2K4 P45985 1/20 0.40
USP30 Q70CQ3 1/20 0.38
GSK3B P49841 7/20 0.37
DYRK1A Q13627 7/20 0.37
TTK P33981 3/20 0.36
CREBBP Q92793 5/20 0.36
RET P07949 1/20 0.35
WNT1 P04628 1/20 0.35
MAPK1 P28482 1/20 0.34
CLK2 P49760 1/20 0.34
CLK3 P49761 1/20 0.34
BRD4 O60885 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19960726 0.90 MAP4K1 (0.40) ALDH1A1HTTSMN1; SMN2L3MBTL1MAP2K4
SCHEMBL29746577 0.87 MAP4K1 (0.41) ALDH1A1HTTSMN1; SMN2L3MBTL1MAP2K4
SCHEMBL19950299 0.87 TTK (0.37) ALDH1A1HTTSMN1; SMN2L3MBTL1TTK
SCHEMBL29746572 0.87 TTK (0.37) ALDH1A1HTTSMN1; SMN2L3MBTL1TTK
SCHEMBL19949978 0.87 MAP4K1 (0.41) ALDH1A1HTTSMN1; SMN2L3MBTL1MAP2K4
SCHEMBL28988366 0.86 MAP2K4 (0.42) MAP2K4USP30GSK3BDYRK1ATTK
SCHEMBL19950162 0.86 MAP4K1 (0.44) ALDH1A1HTTSMN1; SMN2L3MBTL1TTK
SCHEMBL29746530 0.86 MAP4K1 (0.44) ALDH1A1HTTSMN1; SMN2L3MBTL1TTK
SCHEMBL29746687 0.84 MAP4K1 (0.36) ALDH1A1HTTSMN1; SMN2L3MBTL1TTK
SCHEMBL19950412 0.84 MAP4K1 (0.36) ALDH1A1HTTSMN1; SMN2L3MBTL1TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384778-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2025-08-12 US disclosed
US-20240287059-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-08-29 US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
CN-109923114-B Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer 因赛特公司 2022-11-01 CN disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 EP disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 US disclosed
US-10934288-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2021-03-02 US disclosed
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-19 US disclosed
US-10435405-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-10-08 US disclosed
EP-3510032-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER Incyte Corporation (US) 2019-07-17 EP disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049200-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384778-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-10934288-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-10435405-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885
US-20240287059-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 ALDH1A1 2205/4885HTT 2771/4885SMN1; SMN2 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.